MF Frontline announced in JnJ presentation
Posted: Wed Oct 19, 2016 4:14 pm
For discussion, after the JnJ Q3 Report:
Links to the JnJ Q3 presentation:
http://seekingalpha.com/article/4012737 ... all-slides
http://files.shareholder.com/downloads/ ... peline.pdf
by MedTechBio, SA 19 October 2016:
Whoa, I almost fell off my chair. Page 45 has MF frontline Imetelstat filing in addition to the R/R. We all knew that was likely, but first time JNJ or Geron published this that I can recall.
======
by CuriosityKilledTheCat, SA 19 October 2016:
Janssen's intention to file for frontline MF was publicly disclosed as far back as May 20, 2015, during it's Pharma Analyst's Day conference:
http://files.shareholder.com/downloads/ ... _Final.pdf
On page 206 of the presentation, Imetelstat is listed as a "planned filing" 2015-2019 in MF R/R and MDS low/intermediate risk and under "Selected Early To Mid-Stage Pipeline (filing expected beyond 2019) one can find MF frontline, MDS high risk and AML R/R.
What has changed according to the new presentation is imetelstat's lead indication MF R/R is now expected to be filed in 2018 (follow magic's link to page 33) whereas filing for that indication was originally anticipated to occur in 2017 (follow the above link to page 221). However, what also has changed is the anticipated filing date of MF frontline. As I note above it was originally anticipated to occur beyond 2019 and now is expected to occur sometime before 2019 (magic's link to page 45). What this change tells me is Janssen has prioritized MF frontline (vs. AML R/R and MDS high risk). It also tells me to expect an announcement in the not-too-distant future of the start of the MF frontline trial.
======
Any opinions here?
Links to the JnJ Q3 presentation:
http://seekingalpha.com/article/4012737 ... all-slides
http://files.shareholder.com/downloads/ ... peline.pdf
by MedTechBio, SA 19 October 2016:
Whoa, I almost fell off my chair. Page 45 has MF frontline Imetelstat filing in addition to the R/R. We all knew that was likely, but first time JNJ or Geron published this that I can recall.
======
by CuriosityKilledTheCat, SA 19 October 2016:
Janssen's intention to file for frontline MF was publicly disclosed as far back as May 20, 2015, during it's Pharma Analyst's Day conference:
http://files.shareholder.com/downloads/ ... _Final.pdf
On page 206 of the presentation, Imetelstat is listed as a "planned filing" 2015-2019 in MF R/R and MDS low/intermediate risk and under "Selected Early To Mid-Stage Pipeline (filing expected beyond 2019) one can find MF frontline, MDS high risk and AML R/R.
What has changed according to the new presentation is imetelstat's lead indication MF R/R is now expected to be filed in 2018 (follow magic's link to page 33) whereas filing for that indication was originally anticipated to occur in 2017 (follow the above link to page 221). However, what also has changed is the anticipated filing date of MF frontline. As I note above it was originally anticipated to occur beyond 2019 and now is expected to occur sometime before 2019 (magic's link to page 45). What this change tells me is Janssen has prioritized MF frontline (vs. AML R/R and MDS high risk). It also tells me to expect an announcement in the not-too-distant future of the start of the MF frontline trial.
======
Any opinions here?